21:01 , Dec 8, 2017 |  BC Week In Review  |  Company News

Collegium gets U.S. commercial rights to Nucynta from Depomed

Depomed Inc. (NASDAQ:DEPO) granted Collegium Pharmaceutical Inc. (NASDAQ:COLL) exclusive, U.S. rights to commercialize its Nucynta tapentadol analgesic franchise, which includes Nucynta tapentadol immediate release and Nucynta ER, an extended-release formulation of the mu opioid receptor...
22:53 , Nov 3, 2017 |  BC Extra  |  Company News

Management tracks: Tissue Regenix, Therapix

Regenerative medical device company Tissue Regenix Group plc (LSE:TRX) named Steve Couldwell CEO. A Tissue Regenix director since 2013, Couldwell was COO of global biosurgery at Sanofi (Euronext:SAN; NYSE:SNY). Cannabinoid company Therapix Biosciences Ltd. (Tel...
22:55 , Oct 18, 2017 |  BC Extra  |  Company News

Management tracks: Gilead, Ipsen, Depomed

Gilead Sciences Inc. (NASDAQ:GILD) promoted Alessandro Riva to EVP of oncology therapeutics. He was SVP of hematology and oncology therapeutic area head. Before joining Gilead this year, he was head of global oncology development at...
23:48 , Aug 22, 2017 |  BC Extra  |  Company News

Management tracks: Akari, Turnstone, Iconic

Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) named David Horn Solomon CEO, effective Aug. 28. He was managing partner at Sund Capital, and was previously CEO of Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) and...
23:35 , Aug 8, 2017 |  BC Extra  |  Company News

Depomed plummets on reduced sales guidance

Four weeks after reiterating its 2017 revenue guidance, Depomed Inc. (NASDAQ:DEPO) disappointed investors by lowering its top-line outlook when it reported 2Q17 earnings on Monday after market close. The company lost a third of its...
18:49 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Ironwood's IW-3718 meets primary in Phase IIb to treat GERD

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) said top-line data from a double-blind, U.S. Phase IIb trial in 282 patients with uncontrolled gastroesophageal reflux disease (GERD) showed that twice-daily 1,500 mg oral IW-3718 plus a proton pump inhibitor...
23:37 , Jul 17, 2017 |  BC Extra  |  Company News

Management tracks

Osteoporosis and cancer play Radius Health Inc. (NASDAQ:RDUS) named Jesper Hoiland president and CEO. He was president of the U.S. division at Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO). Gene therapy company Freeline Therapeutics (London, U.K.) appointed...
23:31 , May 17, 2017 |  BC Extra  |  Company News

Management tracks

Protein therapeutics company Molecular Partners AG (SIX:MOLN) named Patrick Amstutz CEO. Amstutz had been acting CEO since the November 2016 resignation of Christian Zahnd. Autoimmune and inflammatory disease company Akari Therapeutics plc (NASDAQ:AKTX) said CEO...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Cebranopadol: Phase III data

The double-blind, international Phase III CORAL trial in 125 patients with moderate to severe chronic cancer pain currently on opioid treatment showed that once-daily oral cebranopadol met the primary endpoint of non-inferiority to twice-daily oral...
07:00 , Sep 30, 2016 |  BC Extra  |  Clinical News

Gruenenthal's cebranopadol meets Phase III pain endpoint

Gruenenthal Group (Aachen, Germany) said once-daily cebranopadol ( GRT6005 ) met the primary endpoint of a Phase III study to treat cancer-related pain. The company said cebranopadol was non-inferior, as well as superior, to twice-daily...